Clinical trial
Methylprednisolone With or Without Daclizumab in Treating Patients With Acute…
NCT00053976 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00053976 |
|---|---|
| Title | Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease |
| Official title | Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Biological, Drug |
| Interventions | Daclizumab, methylprednisolone, Placebo |
| Enrollment | 105 |
| Start date | Jan 1, 2001 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2004 |
| First posted | Feb 6, 2003 |
| Last update posted | Jan 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: